This report analyzes shared savings programs designed to incentivize biosimilar adoption across European healthcare systems. It examines how financial incentives for providers and institutions can accelerate uptake while reinvesting savings into patient care. Program design varies widely by country, influencing effectiveness and sustainability. The report highlights successful models that combine clear governance, clinician engagement, and transparent reinvestment mechanisms. It concludes that well-structured shared savings programs can align stakeholder incentives, support sustainable biosimilar markets, and improve access without compromising quality of care.

Join for free to read